Patents

Prolight has a strong patent portfolio

- The patent situation for the digital immunoassay, Psyros™

For the digital immunoassay platform, PsyrosTM, six patent applications are filed. The first three applications have completed the international PCT (Patent Cooperation Treaty) phase and are now being pursued in different territories worldwide. These three applications cover the core technology of single molecule counting.
 
The fourth and fifth applications have now entered the international PCT phase. The fourth application covers various aspects of multiplexing (i.e., detecting several different biomarkers at the same time on a single sample). By using Prolight’s unique single molecule counting technology, multiplexing can be carried out in a single drop of blood on a sensor without needing to split the sample into separate areas.

The fifth application uses a similar approach to allow the measurement of the same biomarker at both very low and very high concentrations simultaneously. The benefit of the unique technology is that the sample size remains extremely small, and that the sensor is easy to manufacture, yet also offering the ability to detect very low concentrations of biomarkers with high specificity. 
 
The sixth application has been filed at the UK patent office and increases the scope of the technology by allowing any type of fluorophore to be used, including quantum dots and lanthanide fluorophores, in addition to traditional organic fluorophores. The sixth application will enter the international PCT phase in November 2025.

- The patent situation for MicroFlex

For MicroFlex, the patent portfolio consists of five registered patents (two in the US, two in the EU, and one in Sweden) and three patent applications that have advanced to the national phase and are now being pursued in various territories.

 

One of the patent applications pertains to how the sampling tube can be directly integrated into the test card. This enables a very simple workflow for all types of clinical environments. No specially trained personnel are needed to pipette and centrifuge the blood sample. MicroFlex thus creates the conditions to offer a fully automated platform for immunodiagnostics.

 

The most recently approved patent (October 2024) concerns a European patent based on a groundbreaking solution for separating plasma from whole blood in a liquid-based consumable. The separation produces high-quality plasma, requires minimal physical space, and is performed in a short amount of time, unlocking new potential business opportunities by integrating the technology into other liquid-based disposable systems.

Subscribe